GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Akums Drugs and Pharmaceuticals Ltd

Akums Drugs names Sanjay Kumar Senior Management Personnel

MANAGEMENT ● No Immediate Change LOW RISK
📅 Filed on BSE: 02 Nov 2026, 05:34 PM IST  ·  BSE ID: 0b6a1192-699a-4b98-9548-da676747ed5d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company appointed a new senior manager and reported its latest financial results.
🤖 AI Summary
  • Sanjay Kumar appointed Senior Management Personnel, effective November 02, 2026.
  • Appointment approved by Akums Drugs Board based on Nomination Committee recommendation.
  • Company disclosed unaudited financial results for the quarter ended September 30, 2026.
  • 100% IPO proceeds have been fully utilized, eliminating deviation reporting requirement.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Company incorporated
Information not provided in this filing.
IPO Proceeds Utilized
100%
🏢 How This Affects the Company
📈
Business Impact
Designation of senior management personnel is a standard corporate governance event, not directly impacting immediate business operations.
💰
Financial Impact
The financial results for Q2 FY27 are disclosed. 100% IPO proceeds utilization confirms prior funding deployment.
⚙️
Operational Impact
Mr. Sanjay Kumar's designation as Senior Management Personnel indicates a formal recognition of his role in operations.
⚠️
Risk Impact
No new risks are introduced by this management designation. Continued compliance with SEBI LODR regulations is maintained.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this announcement.
👤
Who Is Affected
This designation affects all shareholders by adhering to corporate governance best practices for senior management.
🔍
Management Signal
The appointment signals management's structured approach to organizational roles and compliance with regulatory requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results disclosure
Any further senior management changes
Confirmation of operational performance in upcoming quarters
LOW RISK Routine management designation and standard financial reporting.
💡 Investor Takeaway
Akums Drugs designated Sanjay Kumar as Senior Management Personnel and released Q2 FY27 unaudited financial results. 100% IPO proceeds are utilized.
📅 Company Track Record
Akums Drugs and Pharmaceuticals Ltd. previously announced the cessation of Mr. Sunil Jaiswal as Senior Management Personnel on October 31, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
Who has been appointed as Senior Management Personnel at Akums Drugs and Pharmaceuticals Ltd?
Mr. Sanjay Kumar, President – Operations, has been designated as Senior Management Personnel of the Company.
When was Mr. Sanjay Kumar's designation approved?
The Board of Directors approved the designation of Mr. Sanjay Kumar as Senior Management Personnel on November 02, 2026.
What is the status of Akums Drugs and Pharmaceuticals Ltd's IPO proceeds?
Akums Drugs and Pharmaceuticals Ltd has confirmed that 100% of the Initial Public Offer proceeds have been fully utilized.
What financial results did Akums Drugs and Pharmaceuticals Ltd disclose?
The company disclosed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.